Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1142MR)

This product GTTS-WQ1142MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1142MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15400MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ11193MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ6165MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ12094MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ14423MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ8554MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ52MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ2727MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-139
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW